Therapy of refractory nontuberculous mycobacterial lung disease

The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tu...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Current opinion in infectious diseases Ročník 25; číslo 2; s. 218
Hlavní autori: Griffith, David E, Aksamit, Timothy R
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.04.2012
Predmet:
Anti-Bacterial Agents - therapeutic use
Communicable Diseases, Emerging - therapy
Drug Resistance, Bacterial
Humans
Lung Diseases - microbiology
Lung Diseases - therapy
Mycobacterium avium-intracellulare Infection - therapy
Mycobacterium Infections - therapy
Risk Factors
Treatment Failure
ISSN:1473-6527, 1473-6527
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the USA. Clinicians are therefore encountering these patients with increasing frequency, with the attendant multiple therapeutic challenges presented by NTM lung disease including relatively frequent (compared with tuberculosis) treatment failure. Critical elements for the successful treatment of Mycobacterium avium complex (MAC) lung disease include aggressive first therapeutic attempts and avoidance of the emergence of macrolide-resistant MAC strains, which are associated with worse treatment response and increased mortality. Reliably effective therapy for M. abscessus lung disease remains elusive but still usually requires parenteral agents. Lung resection surgery for selected patients is an important adjunct for both MAC and M. abscessus lung disease. Aside from surgery and parenteral antibiotics, there are very few data to support the efficacy of other drugs or interventions for patients who have failed the first-line therapy. Clinicians who manage NTM lung disease will inevitably encounter patients who fail the first-line therapy. The choices for effective treatment of these patients are depressingly sparse. It is critically important to avoid creation of macrolide-resistant MAC strains and to carefully choose those NTM lung disease patients who will benefit from surgery.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1473-6527
1473-6527
DOI:10.1097/QCO.0b013e3283511a64